GNAO1 and movement disorder: Tetrabenazine and neuroleptics seem to be the most effective drugs to treat movement disorders in GNAO1 mutation carriers; in severe drug-resistant cases, bilateral GPi DBS has significantly improved the frequency and severity of exacerbations as well as patients’ motor performances, although the baseline movement disorder seems to remain rather constant even after DBS implant [66, 71,72].